{"id":18375,"date":"2021-07-06T16:05:26","date_gmt":"2021-07-06T11:05:26","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=76028"},"modified":"2021-07-06T16:05:26","modified_gmt":"2021-07-06T11:05:26","slug":"trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/","title":{"rendered":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule"},"content":{"rendered":"

58 Clinical Trial Sites, 11 Countries<\/h4>\n

EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133\/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided encouraging results and supported continuation of the study.<\/p>\n

Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.<\/p>\n

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting. Enrolment of 221 patients was completed three months ahead of schedule. The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.<\/p>\n

\u201cTo have patient enrolment completed three months ahead of schedule, despite the global pandemic, reinforces the strength of commitment of TRIO\u2019s investigator network,\u201d stated Dr. Vanesa Quiroga, a member of the trial\u2019s Steering Committee, GEICAM and Catalan Institute of Oncology. \u201cThe scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.\u201d<\/p>\n

More information on the coopERA Breast Cancer trial (WO42133\/TRIO038\/coopERA) can be found at\u00a0clinicaltrials.gov<\/u><\/a>\u00a0(NCT04436744).<\/p>\n

About TRIO<\/u><\/strong>
\nTRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO\u2019s global reach is expansive. Our goal as an academic clinical research organization is to find the shortest path to saving lives. Additional information on TRIO can be found by visiting\u00a0https:\/\/www.trioncology.org<\/a>. Interested parties may also follow TRIO on Twitter (twitter.com\/TRIOncology<\/a>).<\/p>\n

TRIO Media Inquiries:<\/u><\/strong>
\nLauna Aspeslet, PhD
\nCEO, TRIO
\nEmail:\u00a0<\/strong>launa.aspeslet@trioncology.org<\/a>
\nPhone:\u00a0<\/strong>780-702-2260<\/p>\n","protected":false},"excerpt":{"rendered":"

58 Clinical Trial Sites, 11 Countries EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) \u2014 Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133\/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"\nTRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette\" \/>\n<meta property=\"og:description\" content=\"58 Clinical Trial Sites, 11 Countries EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) \u2014 Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133\/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T11:05:26+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\"},\"headline\":\"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule\",\"datePublished\":\"2021-07-06T11:05:26+00:00\",\"dateModified\":\"2021-07-06T11:05:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\"},\"wordCount\":358,\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\",\"name\":\"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\"},\"datePublished\":\"2021-07-06T11:05:26+00:00\",\"dateModified\":\"2021-07-06T11:05:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"name\":\"Myanmar News Gazette\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\",\"name\":\"Myanmar News Gazette\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"contentUrl\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Myanmar News Gazette\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewsgazette.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/","og_locale":"en_US","og_type":"article","og_title":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette","og_description":"58 Clinical Trial Sites, 11 Countries EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) \u2014 Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133\/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion [\u2026]","og_url":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/","og_site_name":"Myanmar News Gazette","article_published_time":"2021-07-06T11:05:26+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#article","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f"},"headline":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule","datePublished":"2021-07-06T11:05:26+00:00","dateModified":"2021-07-06T11:05:26+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/"},"wordCount":358,"publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/","url":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/","name":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule - Myanmar News Gazette","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/#website"},"datePublished":"2021-07-06T11:05:26+00:00","dateModified":"2021-07-06T11:05:26+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewsgazette.com\/trio-completes-enrolment-for-phase-2-giredestrant-early-breast-cancer-trial-ahead-of-schedule\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewsgazette.com\/#website","url":"https:\/\/myanmarnewsgazette.com\/","name":"Myanmar News Gazette","description":"","publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewsgazette.com\/#organization","name":"Myanmar News Gazette","url":"https:\/\/myanmarnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","contentUrl":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","width":200,"height":200,"caption":"Myanmar News Gazette"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/18375"}],"collection":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/comments?post=18375"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/18375\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/media?parent=18375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/categories?post=18375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/tags?post=18375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}